Modern evidence-based medicine shows that statin can not only regulate lipids, but also repair damaged vascular endothelium, inhibit the inflammatory response of atherosclerotic plaques, form a protective layer, stabilize or even reverse them, reverse thickened arterial intima and thus improve arterial stenosis, as well as antiplatelet coagulation, which can significantly improve cardiovascular and cerebrovascular prognosis. A large number of studies have confirmed that statin can indeed reduce cardiovascular accidents, and the longer the course of treatment, the better. It is generally believed that long-term use can reduce the risk of death from myocardial infarction and cerebral infarction by about 20%-30%. And there are large-scale clinical studies proving that taking it for more than 6 years can reduce cardiovascular and cerebrovascular events by 30% with small doses and by 50% with medium and large doses. The guidelines state that statins should be used in all patients with coronary artery disease (regardless of lipid levels). The target LDL-C in patients with coronary artery disease should be <2.60 mmol/L (100 mg/dl), and for very high-risk patients (coronary artery disease combined with diabetes mellitus or acute coronary syndrome), the therapeutic target LDL-C is <2.07 mmol/L (80 mg/dl). Cerebrovascular disease is a critical condition such as coronary artery disease, LDL-C >3.35mmol/L (130mg/dl) should start therapeutic lifestyle, if the target LDL-C value cannot be reached: LDL-C <2.60mmol/L (100mg/dl), statin therapy should be initiated. Long-term statin use is safe. Before and during treatment, clinical symptoms and changes in liver enzymes (ALT) and muscle enzymes (CK) should be monitored regularly; if ALT < 3 times the upper limit of normal and CK < 5 times the upper limit of normal, discontinuation is not required. If the ALT exceeds 3 times the upper limit of normal and CK 5 times the upper limit of normal, discontinue the drug for observation, reduce the dosage and retest after recovery.